Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

Caprion Biosciences and HistoGeneX announce merger

Caprion Biosciences and HistoGeneX have announced an agreement to combine their respective businesses, according to a press announcement. Financial terms of the transaction were not announced. The new partnership is aimed at creating a global leader in immune monitoring, protein characterization, and tissue pathology solutions for immunotherapy and drug development. The deal is backed by private equity firm Arsenal Capital Partners.


M&A,private equity